CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T
Bio Pharma Dive
OCTOBER 12, 2021
The gene editing company aims to expand its trial and add a second dose to improve effectiveness. However, safety worries have emerged since the FDA ordered CRISPR's rival Allogene to suspend clinical work.
Let's personalize your content